Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
The U.S. Food and Drug Administration (FDA) has officially approved Sotyktu® (generic name: Deucravacitinib), developed by Bristol Myers Squibb, for the treatment of active psoriatic arthritis in adults.

The U.S. Food and Drug Administration (FDA) has officially approved Sotyktu® (generic name: Deucravacitinib), developed by Bristol Myers Squibb, for the treatment of active psoriatic arthritis in adults.

老虎证券老虎证券2026/03/07 03:08
Show original
This decision provides patients with a brand new oral treatment option, which is expected to significantly improve their quality of life.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!